Translating Advanced Microbiome Science into Clinical & Commercial Impact, to Build Investor Confidence and Deliver Safe, Effective Solutions for End Consumers.
Momentum returned to microbiome-based therapies. Companies like Vedanta Biosciences, Siolta Therapeutics, Microbiotica and Seres Therapeutics moved closer to commercialisation across C. diff, oncology and immune-related diseases. Recent financings, including mbiomics (€30M), Kanvas Biosciences ($48M) and EnteroBiotix (£19M), alongside the Gates Foundation’s $2.5 billion commitment to women’s health, signalled growing confidence in the field.
But momentum alone isn’t enough. Unclear mechanisms, inconsistent clinical efficacy, and limited pharma and investor trust still stiood between promising science and real-world patient impact.
That’s why the 11th Microbiome Movement USA Summit returned to Boston last November. You joined C-suite, VP and Director-level leaders across pioneering biopharma, regulators, and both microbiome-curious and first-time investors to answer one critical question:
How do you translate microbiome biology into clinically validated, commercially viable therapies to effectively treat your indication of interest?
You experienced networking opportunities and insights from Ferring Pharmaceuticals, Nestlé Health Science, Vedanta Biosciences, MRM Health, Seventure Partners, The Gates Foundation, and more, as you discovered how to demonstrate robust clinical efficacy, rebuild stakeholder confidence, and position your program for regulatory and commercial success.
I’m excited to see examples of how classical pharmacologic principles can be modified and used in rational development of live microbiota-based products targeting the gut microbiome.
2026 Speaker, Chief Medical Officer, Gut-Brain-Axis Therapeutics
I appreciate hearing from experts in the microbiome field, particularly those CSOs/CEOs of the more mature startups.
2025 Speaker, Chief Scientific Officer, Kanvas Biosciences
I really enjoyed that most of the key big players attended. I also liked the contrast between consumer and pharma products.
2025 Speaker, Postdoctoral Research Fellow, Biostatistics, Harvard Medical School
Explore the 2026 Event Guide
- Join >80% C-level, VPs, and Directors to identify and connect with key opinion leaders in the microbiome space
- See the LBP and FMT coverage to pinpoint sessions most relevant to your program
- See active investors and strategic partners attending to refine your funding and partnering strategy
- Pharma insights from Ferring and ex-Takeda leaders to understand how to secure pharma support
- Learn from Vedanta, MRM Health, and AOBiome to overcome clinical setbacks and scale microbiome-based therapies
2026 Official Partners
Attending Companies Included
Explore the 2026 Agenda
Dive into real-world strategies tackling microbiome credibility, clinical efficacy, and regulatory hurdles so you can move your program forward with confidence.
Partner With Us in 2027
Position your solution at the centre of microbiome dealmaking as biotechs actively seek partners to validate, fund, and scale their programs.
Join Biopharma Experts
Connect with microbiome leaders across R&D, CMC, and BD to exchange insights, overcome shared challenges, and build partnerships that accelerate clinical and commercial success.